PDS Health®, a leading integrated healthcare support organization, provided $92,079 in donated oral health care to 27 ...
The majority of the PDS Health-affiliated practices share a perception among former patients that the staff exaggerated their ...
Analysts expect PDS Biotechnology to report an earnings per share (EPS) of $-0.20. PDS Biotechnology bulls will hope to hear ...
Upfront with up to an Additional $5.8 million of Aggregate Gross Proceeds upon the Cash Exercise in Full of WarrantsPRINCETON, N.J., Nov. 11, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation ...
Company Announced Completion of VERSATILE-002 Phase 2 trial of PDS0101 + Pembrolizumab in HPV16-Positive Recurrent/Metastatic Head and Neck ...
Pds Biotechnology (($PDSB)) has held its Q3 earnings call. Read on for the main highlights of the call. The recent earnings call of PDS ...
PDS Biotechnology Corporation (NASDAQ: PDSB) Q3 2025 Earnings Call Transcript November 13, 2025 ...
The National Weather Service issued another "Particularly dangerous situation" -- or PDS -- warning - for extreme red-flag conditions. It's the 5th PDS warning since November. "Ultimately every ...
4don MSN
PDS Biotech outlines trial protocol amendment for accelerated PFS endpoint in HPV16-positive cancer
Get key insights from PDS Biotech’s Q3 2025 earnings call, including regulatory updates for PDS0101 in HPV16+ cancer and financial highlights.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback